Many of the nonconfidential advances in our premier research and development pipeline are shared through an extensive list of peer-reviewed publications and posters presented at international conferences.Medical and Scientific Publications
Narsoplimab (OMS721) Publications:
Narsoplimab is an investigational product not approved by any regulatory agency.
2023
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists
Mahmoudjafari Z, Alencar MC, Alexander M, Johnson DJ, Yeh J, Evans MD. Bone Marrow Transplantation. 2023; in press.
Systematic review of signs and symptoms associated with hematopoietic stem cell transplantation-associated thrombotic microangiopathy
Dandoy CE, Tsong WH, Sarikonda K, McGarvey N, Perales M-A. Transplantation and Cellular Therapy. 2023;29(4):282.e1-282.e9.
2022
Systematic review of signs and symptoms associated with hematopoietic stem cell transplantation-associated thrombotic microangiopathy
Dandoy CE, Tsong WH, Sarikonda K, McGarvey N, Perales M-A. Transplantation and Cellular Therapy. 2023;29(4):282.e1-282.e9.
Trial in progress: An open-label, multi-center phase 2 study evaluating efficacy and safety of the MASP-2 inhibitor narsoplimab in pediatric patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
Pullman W, Brough M, Soto C, Meng T-C. Blood. 2022;140(suppl 1):8493-8494.
Narsoplimab treatment for recurrent IgA nephropathy stabilized eGFR and proteinuria
Storrar J, Rainone F, Middleton R, Barratt J. J Am Soc Nephrol. 2022;33:195.
Use of narsoplimab in a paediatric patient with IgA nephropathy
Oni L, McCormack V, Jones CA, Barratt J. J Am Soc Nephrol. 2022;33:959.
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy
Elhadad S, Chadburn A, Magro C, et al. Bone Marrow Transplant. 2022;57(9):1445-1447.
Premortem skin biopsy assessing microthrombi, interferon type I antiviral and regulatory proteins, and complement deposition correlates with coronavirus disease 2019 clinical stage
Laurence J, Nuovo G, Racine-Brzostek SE, et al. Am J Pathol. 2022;192(9)1282-1294.
Inhibition of the lectin pathway of complement ameliorates hypocomplementemia and restores serum bactericidal activity in patients with severe COVID-19
Lynch NJ, Chan ACY, Ali YM, et al. Clin Transl Med. 2022;12(7):e980.
Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation–associated thrombotic microangiopathy
Khaled SK, Claes K, Goh YT, et al. J Clin Oncol. 2022;40(22):2447-2457.
Secondary complement deficiency impairs anti-microbial immunity to Klebsiella pneumoniae and Staphylococcus aureus during severe acute COVID-19
Ali YM, Lynch NJ, Khatri P, et al. Front Immunol. 2022;13:841759
Compassionate use narsoplimab to treat transplant associated thrombotic microangiopathy in a pediatric patient with multi-organ failure
Schoettler M, Bryson E, Deeb L, et al. Bone Marrow Transplant. 2022;57(suppl 1):350.
Lectin pathway inhibitor for transplant-associated thrombotic microangiopathy
Ganatra P, Kakunje M, Mishra V, Pandrowala A, Hiwarkar P. Bone Marrow Transplant. 2022;57(suppl 1):349.
Trial design: Phase 3 randomized, double-blind, placebo-controlled study of narsoplimab safety and efficacy in IgA nephropathy (ARTEMIS-IGAN)
Lafayette R, Rovin B, Floege J, et al. Kidney Int Rep. 2022;7(2):S57.
2021
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy
Gavriilaki E, Ho VT, Schwaeble W, et al. Exp Hematol Oncol. 2021;10:57.
Characterization of narsoplimab, a selective inhibitor of lectin pathway-mediated complement activation and thrombosis
Dudler T, Yaseen S, Freeman J, et al. Mol Immunol. 2021;141:145.
Real world use of narsoplimab in a case of severe HSCT-TMA
Long-term Phase 2 efficacy of the MASP-2 inhibitor narsoplimab for treatment of severe IgA nephropathy
Reduction of urinary levels of lectin pathway complement components in an IgA vasculitis patient after MASP-2 inhibition with narsoplimab
Lectin pathway mediates complement activation by SARS-CoV-2 proteins
Narsoplimab (OMS721) treatment contributes to improvements in organ function in adult patients with high-risk transplant-associated thrombotic microangiopathy
Perales M, Cairo M, Duarte R, et al. HemaSphere. 2021;5(suppl 2):79.
Narsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA): Subgroup analyses
Rambaldi A, Claes K, Goh YT, et al. Bone Marrow Transplant. 2021;56:147-149.
Clinical pharmacology and population pharmacokinetic/pharmacodynamic modeling of lectin pathway inhibition by narsoplimab (OMS721)
In acute HSCT/BMT-TMA the activation of the lectin pathway induces C5b-9 formation on endothelial cells and favors microvascular thrombosis
Narsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab
Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. Clin Exp Immunol. 2021;203(1):96-104.
2020
Development of pharmacodynamic assays to assess ex vivo MASP-2 inhibition and their use to characterize the pharmacodynamics of narsoplimab (OMS721) in humans and monkeys
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
Safety, tolerability, and effect of narsoplimab (OMS721), a novel MASP-2 inhibitor for the treatment of IgA nephropathy
Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis
Narsoplimab (OMS721) for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy
Rambaldi A, Smith M, Whitaker S, Khaled S. HemaSphere. 2020;4(suppl 1):92.
MASP-2 inhibition as a potential strategy for the management of IgA nephropathy
2019
MASP-2 levels following allogeneic hematopoietic stem cell transplantation in adults: correlation with development of a thrombotic microangiopathy and implications for therapy with anti-complement agents
Elhadad S, Van Biesen K, Chapin J, Ahamed J, Laurence J. Blood. 2019;134(suppl 1):3305.
Absence of the lectin activation pathway of complement ameliorates proteinuria-induced renal injury
Interim results from an ongoing phase 2 study evaluating the use of a MASP-2 inhibitor for the treatment of IgA nephropathy
Barratt J, Leifke E, Whitaker S, DeTulleo L, Lafayette R. Nephrology Dialysis Transplant. 2019;34(suppl 1):111.
2018
Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction
Clark JE, Dudler T, Marber MS, Schwaeble W. Open Heart. 2018;5(1):e000652.
Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)
Rambaldi A, Khaled S, Smith M, et al. HemaSphere. 2018;2(suppl 1):312-313.
2017
The effect of OMS721 on proteinuria in patients with IgA nephropathy
Block G, Whitaker S. Nephrology Dialysis Transplant. 2017;32(suppl 3):143.
Maintenance of remission following completion of OMS721 treatment in Patients with IgA nephropathy (IgAN)
Block G, Whitaker S. J Am Soc Nephrol. 2017;28:749-750.
Effective treatment of GvHD-associated transplant-associated microangiopathy with a novel inhibitor of the lectin pathway of complement
Early results of a phase 2 study using OMS721 in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)
Khaled SK, Kwong YL, Smith M, Metjian A, Whitaker S. Biol Blood Marrow Transplant. 2017;23:S282-S283.
Dose-finding clinical trial of OMS721 for the treatment of atypical hemolytic uremic syndrome (aHUS) – stage 1 results
Nowicki M, Wiecek A, Massart A, Weekers L, Whitaker S, Miglinas M. Presented at: World Congress of Nephrology (WCN); April 21-25, 2017; Mexico City, Mexico.
Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2
Yaseen S, Demopulos G, Dudler T, et al. FASEB J. 2017;31(5):2210-2219. doi:10.1096/fj.201601306R.
Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient
2016
Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1
Orsini F, Chrysanthou E, Dudler T, et al. J Neuroinflammation. 2016;13(1):213. doi:10.1186/s12974-016-0684-6.
2014
Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4
2012
The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection
2011
Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury
2010
Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot
OMS906 Publications:
OMS906 is an investigational product not approved by any regulatory agency.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the alternative pathway MASP-3 inhibitor OMS906 in a phase 1 study of healthy subjects
Pullman W, Humphreys J, Philpot E, Cummings WJ. Blood. 2022;140(suppl 1):5801-5802.
In vivo inhibition of alternative pathway activity via MASP-3 inhibitor OMS906
Cummings WJ, Li Y, Shaffer K, Freeman J, Yabuki M, Dudler T. Molecular Immunology. 2022;150:145.
MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease
Belcher JD, Nguyen J, Chen C, et al. Transl Res. 2022;249:1-12.
Other Publications:
Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission
PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission
de Guglielmo G, Melis M, De Luca MA, et al. Neuropsychopharmacology. 2015;40(4):927-937. doi:10.1038/npp.2014.268.
Selection of targeted mutants from a library of randomly mutagenized ES cells
Horie K, Gaitanaris G, Gragerov A. Methods Mol Biol. 2011;693:283-294. doi:10.1007/978-1-60761-974-1_17.
An inducible and reversible mouse genetic rescue system
Zeng H, Horie K, Madisen L, et al. PLoS Genet. 2008;4(5):e1000069. doi:10.1371/journal.pgen.1000069.
Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding
Zeng H, Gragerov A, Hohmann JG, et al. Mol Cell Biol. 2006;26(24):9352-9363.
Related Pages
